HiberCell Initiates Phase 1a Clinical Trial of HC-5404-FU, an ER Stress Modulator NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- HiberCell, a biotechnology company dedicated to overcoming foundational barriers that prevent patients from living longer, cancer-free lives, today...

HiberCell Closes $67.4 Million Series B Financing and Secures $30 Million Debt Facility from Hercules Capital Proceeds to advance pipeline of clinical product candidates focused on preventing cancer relapse and metastasis NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) -- HiberCell, a biotechnology company...